|
|
ARNA Discussion Board
|
|
||
What to look for regarding Ralinepag results // dax ;)This is the Ralinepag P2 trial: These are the primary endpoints: Primary Outcome Measures:
Here you can find Selexipag data for comparison (Please look at Phase 2 data): "In the phase 2 study, there was no effect on pulmonary vascular resistance (PVR) measured 4 hours after a single selexipag oral dose; however, at Week 17, there was a statistically significant 30% decreasein the geometric mean PVR vs. placebo. There was also a decrease in systemic vascular resistance (SVR) at Week 17, consistent with the expected pharmacology of selexipag. ". "but note that the 6MWD results (from the Phase 2 study and GRIPHON) show small but consistent favorable results for selexipag". See also here: |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
3087 | Re: What to look for regarding Ralinepag results // dax ;) | jg56 | 1 | 5/24/2017 10:29:34 AM |